Oruka Therapeutics (NASDAQ:ORKA) Given “Outperform” Rating at Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a report issued on Thursday, Benzinga reports. They presently have a $165.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 83.48% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. UBS Group increased their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday. Finally, BTIG Research restated a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $89.93 on Thursday. Oruka Therapeutics has a 1 year low of $14.89 and a 1 year high of $115.51. The stock has a market capitalization of $5.95 billion, a PE ratio of -44.30 and a beta of -0.34. The stock has a 50-day simple moving average of $96.79 and a 200-day simple moving average of $75.32.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Analysts predict that Oruka Therapeutics will post -2.42 EPS for the current year.

Insider Activity

In other Oruka Therapeutics news, CEO Lawrence Klein sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares in the company, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the transaction, the insider owned 31,771 shares in the company, valued at $2,935,004.98. This represents a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 122,950 shares of company stock worth $11,528,806. Insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Several institutional investors have recently added to or reduced their stakes in ORKA. BlackRock Inc. acquired a new position in Oruka Therapeutics in the second quarter valued at about $474,916,000. Jupiter Topco LLC acquired a new stake in shares of Oruka Therapeutics during the second quarter worth $130,968,000. Remedium Capital Partners LLC lifted its position in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after acquiring an additional 13,247 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of Oruka Therapeutics by 16.4% in the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after purchasing an additional 208,480 shares in the last quarter. Finally, Avidity Partners Management LP boosted its position in shares of Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after buying an additional 100,000 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 produced deepening psoriasis responses without additional dosing after Week 4. By Week 28, the PASI 100 response rate reached 71.4% and the PASI 90 rate reached 87.3%, supporting the potential for durable disease control from the half-life-extended IL-23p19 antibody. Oruka Therapeutics Week 28 Data Announcement
• Positive Sentiment: Patients who crossed over from placebo also achieved PASI 90 and PASI 100 response rates comparable to those initially treated with ORKA-001, while the therapy maintained a favorable safety and tolerability profile through Week 28. EVERLAST-A Week 28 Results
• Neutral Sentiment: The results remain from a mid-stage Phase 2a study, so investors still need larger and later-stage data to assess efficacy, durability, safety, and the drug’s competitiveness against established psoriasis treatments. The company expects full 52-week EVERLAST-A data in December 2026 and EVERLAST-B Week 16 data in the fourth quarter of 2026. What the Phase 2a Data Means for Shareholders
• Negative Sentiment: Despite the improving response rates, ORKA shares fell as investors appeared to treat the update as insufficient for further upside, potentially reflecting profit-taking and high expectations already embedded in the stock. Reports specifically highlighted that the shares declined despite the deepening responses. Oruka Shares Fall Despite Deepening Week 28 Responses

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.